Malaysian Genomics Resource Centre Berhad (Malaysian Genomics), via its wholly-owned subsidiary MGRC Biopharma Sdn Bhd (MGRC) has partnered with Ant Group Digital Technologies’ (Ant Group) subsidiary to employ blockchain traceability.
In a statement today (Nov 8), Malaysian Genomics plans to integrate MGRC’s expertise in personalised and precision medicine with Ant Group Digital Technologies’ technological acumen, particularly in blockchain traceability.
The partnership revolves around MGRC integrating Ant Group’s AntChain TaaS traceability solution, and is made possible through its strategic local partnerships in the healthcare sector.
“Beyond this integration, both companies are keen on exploring a spectrum of digital ventures that could amplify the efficacy and reach of MGRC’s offerings,” the genomics and pharmaceutical specialist said.
Malaysian Genomics executive chairman Azri Azerai said its alliance with Ant Group Digital Technologies is emblematic of its unwavering commitment to innovation.
“By intertwining blockchain traceability within our production framework, we not only bolster product authenticity but also reinforce our promise of excellence to our stakeholders.
This alliance is a testament to our aspiration of merging state-of-the-art technology with biopharmaceutical expertise,” he said.
MGRC will work together with AntChain Technology Pte Ltd, a subsidiary of Ant Group, for its expertise in blockchain traceability, aside from technical expertise in data analytics and intelligent risk management.
Art Group International Busines general manager Derrick Loi added: “Collaborating with MGRC enriches our journey to help accelerate the digital transformation and digital collaboration across different industries.”